3.77  -0.08 (-2.08%)		07-18 16:00
Open: 3.72 High: 3.9 Volume: 5,801		Pre. Close: 3.85 Low: 3.7 Market Cap: 69(M)

Short term
Mid term
Targets	6-month :	4.67	1-year :	5.45
Resists	First :	4	Second :	4.67
Pivot price	3.75
Supports	First :	3.22	Second :	2.74
MAs	MA(5) :	3.79	MA(20) :	3.58
	MA(100) :	3.9	MA(250) :	4.28
MACD	MACD :	0	Signal :	-0.1
%K %D	K(14,3) :	84.1	D(3) :	84.7
RSI	RSI(14): 50.5
52-week	High :	7.28	Low :	2.74

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ GNTA ] has closed below upper band by 48.3%. Bollinger Bands are 43.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 23 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	3.9 - 3.93	3.93 - 3.95
Low:	3.65 - 3.68	3.68 - 3.7
Close:	3.73 - 3.77	3.77 - 3.81

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.

Tue, 08 Jul 2025
Genenta Science Leads The Charge With 2 Other Promising Penny Stocks - simplywall.st

Wed, 02 Jul 2025
Genenta Science stock maintains Buy rating as Temferon shows promise in GBM - Investing.com

Wed, 19 Mar 2025
Genenta Science Secures €20 Million Financing to Boost Cancer Therapy Development - TipRanks

Thu, 27 Feb 2025
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 - The Globe and Mail

Mon, 13 Jan 2025
"Italy on the Move" returns during the J.P. Morgan Healthcare Conference 2025 - Stock Titan

Thu, 09 Jan 2025
Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	18 (M)
Shares Float	11 (M)
Held by Insiders	39.1 (%)
Held by Institutions	9.8 (%)
Shares Short	3 (K)
Shares Short P.Month	3 (K)

EPS	-0.57
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.68
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-32.9 %
Return on Equity (ttm)	-54.2 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.54
Qtrly Earnings Growth	0 %
Operating Cash Flow	-6 (M)
Levered Free Cash Flow	-4 (M)

PE Ratio	-6.62
PEG Ratio	0
Price to Book value	5.54
Price to Sales	0
Price to Cash Flow	-11.06

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.